Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 296

Results For "MP"

10025 News Found

GSK to invest $30 billion in R&D, manufacturing in US over next 5 years
News | September 17, 2025

GSK to invest $30 billion in R&D, manufacturing in US over next 5 years

Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs


Lilly to build $5 billion manufacturing facility in Virginia
News | September 17, 2025

Lilly to build $5 billion manufacturing facility in Virginia

This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year


Enveric clears FDA feedback milestone, prepares IND submission for EB-003
Clinical Trials | September 17, 2025

Enveric clears FDA feedback milestone, prepares IND submission for EB-003

IND application for EB-003 expected in early 2026


KIMS Hospital Bengaluru commences operations of new hospital in Bengaluru
Hospitals | September 17, 2025

KIMS Hospital Bengaluru commences operations of new hospital in Bengaluru

The state-of-the-art facility is a 450-bedded, multi-specialty tertiary care hospital,


FDA approves Lupin’s Lenalidomide capsules
Drug Approval | September 17, 2025

FDA approves Lupin’s Lenalidomide capsules

Lenalidomide Capsules are indicated for the treatment of adult patients with Multiple myeloma


Syensqo introduces medical-grade Amodel PPA for medical devicess
Medical Device | September 16, 2025

Syensqo introduces medical-grade Amodel PPA for medical devicess

A new medical-grade Amodel PPA delivers high heat resistance, electrically insulative properties, and biocompatibility for advanced single-use medical instruments and assemblies


Libtayo plus chemotherapy demonstrates five-year survival benefit in advanced NSCLC
Clinical Trials | September 16, 2025

Libtayo plus chemotherapy demonstrates five-year survival benefit in advanced NSCLC

Late-breaking data presented at WCLC highlight significant and sustained improvements in overall survival, including more than doubling five-year survival rates compared to chemotherapy alone


Advent to sell generic drugmaker Zentiva to GTCR
News | September 16, 2025

Advent to sell generic drugmaker Zentiva to GTCR

Advent acquired Zentiva from Sanofi in 2018 and transformed the company into a highly successful standalone business